Heron Therapeutics Inc  

(Public, NASDAQ:HRTX)   Watch this stock  
Find more results for NASDAQ:APPA
9.26
+0.03 (0.33%)
Aug 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.08 - 9.50
52 week 6.40 - 15.82
Open 9.28
Vol / Avg. 0.00/183,594.00
Mkt cap 266.85M
P/E     -
Div/yield     -
EPS -3.34
Shares 28.91M
Beta 0.40
Inst. own 92%
Aug 4, 2014
Q2 2014 Heron Therapeutics Inc Earnings Release
Jun 25, 2014
Heron Therapeutics Inc at JMP Securities Healthcare Conference
Jun 2, 2014
Heron Therapeutics Inc at Jefferies Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -101.41% -83.82%
Return on average equity -113.14% -91.56%
Employees 47 -
CDP Score - -

Address

123 SAGINAW DRIVE
REDWOOD CITY, CA 94063
United States - Map
+1-650-3662626 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Heron Therapeutics Inc, formerly A.P. Pharma, Inc. is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform. The Company�s lead product candidate, APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company�s Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.

Officers and directors

Kevin C. Tang Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Robert H. Rosen President, Director
Age: 58
Bio & Compensation  - Reuters
Barry D. Quart Pharm.D. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Mark S. Gelder M.D. Senior Vice President, Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Stephen R. Davis Director
Age: 53
Bio & Compensation  - Reuters
Craig A. Johnson Independent Director
Age: 53
Bio & Compensation  - Reuters
Kimberly J. Manhard Independent Director
Age: 54
Bio & Compensation  - Reuters
John W. Poyhonen Independent Director
Age: 54
Bio & Compensation  - Reuters